Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection

DOI record: { "DOI": "10.3389/fphar.2024.1291212", "ISSN": [ "1663-9812" ], "URL": "http://dx.doi.org/10.3389/fphar.2024.1291212", "abstract": "<jats:p>Thymoquinone TQ, an active ingredient of Nigella Sativa, has been shown to inhibit COVID-19 symptoms in clinical trials. Thymoquinone Formulation (TQF or NP-101) is developed as a novel enteric-coated medication derivative from Nigella Sativa. TQF consists of TQ with a favorable concentration and fatty acids, including palmitic, oleic, and linoleic acids. In this study, we aimed to investigate the roles of individual ingredients of TQF on infection of SARS-CoV-2 variants <jats:italic>in-vitro</jats:italic>, by utilizing Murine Leukemia Virus (MLV) based pseudovirus particles. We demonstrated that NP-101, TQ, and other individual ingredients, including oleic, linoleic, and palmitic acids inhibited SARS-CoV-2 infection in the MLV-based pseudovirus model. A large, randomized phase 2 study of NP-101 is planned in outpatient COVID-19 patients.</jats:p>", "alternative-id": [ "10.3389/fphar.2024.1291212" ], "author": [ { "affiliation": [], "family": "Maen", "given": "Abdelrahim", "sequence": "first" }, { "affiliation": [], "family": "Gok Yavuz", "given": "Betul", "sequence": "additional" }, { "affiliation": [], "family": "Mohamed", "given": "Yehia I.", "sequence": "additional" }, { "affiliation": [], "family": "Esmail", "given": "Abdullah", "sequence": "additional" }, { "affiliation": [], "family": "Lu", "given": "Jianming", "sequence": "additional" }, { "affiliation": [], "family": "Mohamed", "given": "Amr", "sequence": "additional" }, { "affiliation": [], "family": "Azmi", "given": "Asfar S.", "sequence": "additional" }, { "affiliation": [], "family": "Kaseb", "given": "Mohamed", "sequence": "additional" }, { "affiliation": [], "family": "Kasseb", "given": "Osama", "sequence": "additional" }, { "affiliation": [], "family": "Li", "given": "Dan", "sequence": "additional" }, { "affiliation": [], "family": "Gocio", "given": "Michelle", "sequence": "additional" }, { "affiliation": [], "family": "Kocak", "given": "Mehmet", "sequence": "additional" }, { "affiliation": [], "family": "Selim", "given": "Abdelhafez", "sequence": "additional" }, { "affiliation": [], "family": "Ma", "given": "Qing", "sequence": "additional" }, { "affiliation": [], "family": "Kaseb", "given": "Ahmed O.", "sequence": "additional" } ], "container-title": "Frontiers in Pharmacology", "container-title-short": "Front. Pharmacol.", "content-domain": { "crossmark-restriction": true, "domain": [ "frontiersin.org" ] }, "created": { "date-parts": [ [ 2024, 2, 6 ] ], "date-time": "2024-02-06T04:31:58Z", "timestamp": 1707193918000 }, "deposited": { "date-parts": [ [ 2024, 2, 6 ] ], "date-time": "2024-02-06T04:32:02Z", "timestamp": 1707193922000 }, "indexed": { "date-parts": [ [ 2024, 2, 7 ] ], "date-time": "2024-02-07T00:48:33Z", "timestamp": 1707266913632 }, "is-referenced-by-count": 0, "issued": { "date-parts": [ [ 2024, 2, 6 ] ] }, "license": [ { "URL": "https://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2024, 2, 6 ] ], "date-time": "2024-02-06T00:00:00Z", "timestamp": 1707177600000 } } ], "link": [ { "URL": "https://www.frontiersin.org/articles/10.3389/fphar.2024.1291212/full", "content-type": "unspecified", "content-version": "vor", "intended-application": "similarity-checking" } ], "member": "1965", "original-title": [], "prefix": "10.3389", "published": { "date-parts": [ [ 2024, 2, 6 ] ] }, "published-online": { "date-parts": [ [ 2024, 2, 6 ] ] }, "publisher": "Frontiers Media SA", "reference": [ { "DOI": "10.3389/fphar.2022.848676", "article-title": "Thymoquinone's antiviral effects: it is time to be proven in the covid-19 pandemic era and its Omicron variant surge", "author": "Abdelrahim", "doi-asserted-by": "publisher", "first-page": "848676", "journal-title": "Front. Pharmacol.", "key": "B1", "volume": "13", "year": "2022" }, { "key": "B2", "unstructured": "Therapeutic efficacy of Honey and Nigella sativa against COVID-19: a multi-center randomized controlled clinical trial (HNS-COVID-PK)\n AshrafS.\n AshrafS.\n AshrafM.\n ImranM. A.\n KalsoomL.\n SiddiquiU. N.\n 2020" }, { "DOI": "10.3748/wjg.v19.i16.2529", "article-title": "Effects of Nigella sativa on outcome of hepatitis C in Egypt", "author": "Barakat", "doi-asserted-by": "publisher", "first-page": "2529", "journal-title": "World J. Gastroenterol.", "key": "B3", "volume": "19", "year": "2013" }, { "DOI": "10.3390/pathogens11050551", "article-title": "A randomized, double-blind, placebo-controlled, multicenter study to evaluate the safety and efficacy of ThymoQuinone formula (TQF) for treating outpatient SARS-CoV-2", "author": "Bencheqroun", "doi-asserted-by": "publisher", "first-page": "551", "journal-title": "Pathogens", "key": "B4", "volume": "11", "year": "2022" }, { "DOI": "10.1136/openhrt-2020-001424", "article-title": "Manipulation of ACE2 expression in COVID-19", "author": "Chaudhry", "doi-asserted-by": "publisher", "first-page": "e001424", "journal-title": "Open Heart", "key": "B5", "volume": "7", "year": "2020" }, { "DOI": "10.1101/2020.07.10.197988", "article-title": "Identifying SARS-CoV-2 entry inhibitors through drug repurposing screens of SARS-S and MERS-S pseudotyped particles", "author": "Chen", "doi-asserted-by": "publisher", "first-page": "1165", "journal-title": "ACS Pharmacol. Transl. Sci.", "key": "B6", "volume": "3", "year": "2020" }, { "DOI": "10.3389/fcimb.2021.753721", "article-title": "The impact of ACE2 polymorphisms on COVID-19 disease: susceptibility, severity, and therapy", "author": "Chen", "doi-asserted-by": "publisher", "first-page": "753721", "journal-title": "Front. Cell. Infect. Microbiol.", "key": "B7", "volume": "11", "year": "2021" }, { "DOI": "10.1016/j.jare.2018.01.001", "article-title": "Arachidonic acid and other unsaturated fatty acids and some of their metabolites function as endogenous antimicrobial molecules: a review", "author": "Das", "doi-asserted-by": "publisher", "first-page": "57", "journal-title": "J. Adv. Res.", "key": "B8", "volume": "11", "year": "2018" }, { "key": "B9", "unstructured": "U.S. Food and drug administration2022" }, { "DOI": "10.1038/s41598-021-84850-1", "article-title": "Polyunsaturated ω-3 fatty acids inhibit ACE2-controlled SARS-CoV-2 binding and cellular entry", "author": "Goc", "doi-asserted-by": "publisher", "first-page": "5207", "journal-title": "Sci. Rep.", "key": "B10", "volume": "11", "year": "2021" }, { "DOI": "10.1126/science.abc4730", "article-title": "Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy", "author": "Gu", "doi-asserted-by": "publisher", "first-page": "1603", "journal-title": "Science", "key": "B11", "volume": "369", "year": "2020" }, { "DOI": "10.3390/pathogens10030379", "article-title": "The impact of angiotensin-converting enzyme 2 (ACE2) expression on the incidence and severity of COVID-19 infection", "author": "Kaseb", "doi-asserted-by": "publisher", "first-page": "379", "journal-title": "Pathogens", "key": "B12", "volume": "10", "year": "2021" }, { "DOI": "10.1016/j.nmni.2021.100929", "article-title": "Genetic emergence of B.1.617.2 in COVID-19", "author": "Kirola", "doi-asserted-by": "publisher", "first-page": "100929", "journal-title": "New Microbes New Infect.", "key": "B13", "volume": "43", "year": "2021" }, { "DOI": "10.1007/bf01320626", "article-title": "Unsaturated free fatty acids inactivate animal enveloped viruses", "author": "Kohn", "doi-asserted-by": "publisher", "first-page": "301", "journal-title": "Arch. Virol.", "key": "B14", "volume": "66", "year": "" }, { "DOI": "10.1128/AAC.18.6.962", "article-title": "Interaction of polyunsaturated fatty acids with animal cells and enveloped viruses", "author": "Kohn", "doi-asserted-by": "publisher", "first-page": "962", "journal-title": "Antimicrob. Agents Chemother.", "key": "B15", "volume": "18", "year": "" }, { "DOI": "10.1016/j.ctim.2021.102769", "article-title": "Nigella sativa for the treatment of COVID-19: an open-label randomized controlled clinical trial", "author": "Koshak", "doi-asserted-by": "publisher", "first-page": "102769", "journal-title": "Complementary Ther. Med.", "key": "B16", "volume": "61", "year": "" }, { "DOI": "10.1016/j.ctim.2021.102769", "article-title": "Nigella sativa for the treatment of COVID-19: an open-label randomized controlled clinical trial", "author": "Koshak", "doi-asserted-by": "publisher", "first-page": "102769", "journal-title": "Complement. Ther. Med.", "key": "B17", "volume": "61", "year": "" }, { "DOI": "10.3389/fimmu.2022.825256", "article-title": "SARS-CoV-2 variants of concern and variants of interest receptor binding domain mutations and virus infectivity", "author": "Liu", "doi-asserted-by": "publisher", "first-page": "825256", "journal-title": "Front. Immunol.", "key": "B18", "volume": "13", "year": "2022" }, { "DOI": "10.21769/BioProtoc.2035", "article-title": "Murine leukemia virus (MLV)-based Coronavirus spike-pseudotyped particle production and infection", "author": "Millet", "doi-asserted-by": "publisher", "first-page": "e2035", "journal-title": "Bio Protoc.", "key": "B19", "volume": "6", "year": "2016" }, { "DOI": "10.3389/fphar.2017.00295", "article-title": "Thymoquinone as a potential adjuvant therapy for cancer treatment: evidence from preclinical studies", "author": "Mostofa", "doi-asserted-by": "publisher", "first-page": "295", "journal-title": "Front. Pharmacol.", "key": "B20", "volume": "8", "year": "2017" }, { "DOI": "10.1186/s13054-020-03120-0", "article-title": "Role of angiotensin-converting enzyme 2 (ACE2) in COVID-19", "author": "Ni", "doi-asserted-by": "publisher", "first-page": "422", "journal-title": "Crit. Care", "key": "B21", "volume": "24", "year": "2020" }, { "DOI": "10.2337/dbi20-0019", "article-title": "SARS-CoV-2 infections and ACE2: clinical outcomes linked with increased morbidity and mortality in individuals with diabetes", "author": "Obukhov", "doi-asserted-by": "publisher", "first-page": "1875", "journal-title": "Diabetes", "key": "B22", "volume": "69", "year": "2020" }, { "DOI": "10.4314/ajtcam.v10i5.18", "article-title": "Nigella sativa concoction induced sustained seroreversion in HIV patient", "author": "Onifade", "doi-asserted-by": "publisher", "first-page": "332", "journal-title": "Afr. J. traditional, complementary, Altern. Med.", "key": "B23", "volume": "10", "year": "2013" }, { "DOI": "10.4314/ajid.v9i2.6", "article-title": "Seronegative conversion of an HIV positive subject treated with Nigella sativa and honey", "author": "Onifade", "doi-asserted-by": "publisher", "first-page": "47", "journal-title": "Afr. J. Infect. Dis.", "key": "B24", "volume": "9", "year": "2015" }, { "DOI": "10.3390/antiox9100921", "article-title": "Nigella sativa’s anti-inflammatory and antioxidative effects in experimental inflammation", "author": "Pop", "doi-asserted-by": "publisher", "first-page": "921", "journal-title": "Antioxidants", "key": "B25", "volume": "9", "year": "2020" }, { "DOI": "10.1016/j.hermed.2020.100382", "article-title": "Potential benefits of combination of Nigella sativa and Zn supplements to treat COVID-19", "author": "Rahman", "doi-asserted-by": "publisher", "first-page": "100382", "journal-title": "J. Herb. Med.", "key": "B26", "volume": "23", "year": "2020" }, { "DOI": "10.1016/j.cell.2020.08.012", "article-title": "Deep mutational scanning of SARS-CoV-2 receptor binding domain reveals constraints on folding and ACE2 binding", "author": "Starr", "doi-asserted-by": "publisher", "first-page": "1295", "journal-title": "Cell", "key": "B27", "volume": "182", "year": "2020" }, { "DOI": "10.3390/ijms22041695", "article-title": "In silico investigation of the new UK (B.1.1.7) and South African (501Y.V2) SARS-CoV-2 variants with a focus at the ACE2-spike RBD interface", "author": "Villoutreix", "doi-asserted-by": "publisher", "first-page": "1695", "journal-title": "Int. J. Mol. Sci.", "key": "B28", "volume": "22", "year": "2021" }, { "key": "B29", "unstructured": "WHO Coronavirus (COVID-19) dashboard: world health organization2022" }, { "DOI": "10.1038/s41594-020-00549-3", "article-title": "A trimeric human angiotensin-converting enzyme 2 as an anti-SARS-CoV-2 agent", "author": "Xiao", "doi-asserted-by": "publisher", "first-page": "202", "journal-title": "Nat. Struct. Mol. Biol.", "key": "B30", "volume": "28", "year": "2021" } ], "reference-count": 30, "references-count": 30, "relation": {}, "resource": { "primary": { "URL": "https://www.frontiersin.org/articles/10.3389/fphar.2024.1291212/full" } }, "score": 1, "short-title": [], "source": "Crossref", "subject": [ "Pharmacology (medical)", "Pharmacology" ], "subtitle": [], "title": "Individual ingredients of NP-101 (Thymoquinone formula) inhibit SARS-CoV-2 pseudovirus infection", "type": "journal-article", "update-policy": "http://dx.doi.org/10.3389/crossmark-policy", "volume": "15" }